Farnesyl transferase inhibitor R115777 in myelodysplastic syndrome.
Cortes
Jorge
J
D000368:Aged; D000369:Aged, 80 and over; D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors*; D001772:Blood Cell Count; D004268:DNA-Binding Proteins / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D051231:Farnesyltranstransferase; D006801:Humans; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects; D011518:Proto-Oncogene Proteins / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt; D015363:Quinolones / Q000008:administration & dosage* / Q000494:pharmacology; D050796:STAT3 Transcription Factor; D015534:Trans-Activators / Q000187:drug effects; D016896:Treatment Outcome
D004268:DNA-Binding Proteins; D011518:Proto-Oncogene Proteins; D015363:Quinolones; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D015534:Trans-Activators; D019883:Alkyl and Aryl Transferases; D051231:Farnesyltranstransferase; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; C402769:tipifarnib